Open AccessGenome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer
Author(s) -
Federico Rotolo,
Chang-Qi Zhu,
Élisabeth Brambilla,
Stephen L. Graziano,
Ken A. Olaussen,
T. Lechevalier,
Jean-Pierre Pig,
Robert A. Kratzke,
JeanCharles Soria,
Frances A. Shepherd,
Lesley Seymour,
Stefan Michiels,
MingSound Tsao
Publication year - 2018
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2018.05.01
Subject(s) - molecular inversion probe , cdkn2a , medicine , lung cancer , adenocarcinoma , stk11 , hazard ratio , oncology , stage (stratigraphy) , cancer , gene , biology , single nucleotide polymorphism , genetics , kras , confidence interval , colorectal cancer , genotype , paleontology
Adjuvant chemotherapy (ACT) provides modest benefit in resected non-small cell lung cancer (NSCLC) patients. Genome-wide studies have identified gene copy number aberrations (CNA), but their prognostic implication is unknown.